TALS News

Eight IPOs and four SPACs went public this past week. One IPO postponed, UK-based biotech Gyroscope Therapeutics (VISN), citing market conditions. Filing activity maintained a comfortable pace/remained moderate, with seven IPOs and 10 SPACs submitting initial filings. The week’s best performer, Sacramento bank Five Star Bancorp (FSBC)...read more

Talaris Therapeutics, a Phase 3 biotech developing allogeneic cell therapies for organ transplant recipient, raised $150 million by offering 8.8 million shares at $17, within the range of $16 to $18. At pricing, the company commands a fully diluted market value of $736 million. Talaris' initial focus is a proprietary therapeutic approach called Facilitated Allo-HSCT Therapy...read more

Talaris Therapeutics, a Phase 3 biotech developing methods for allogeneic hematopoietic stem cell transplantation, announced terms for its IPO on Monday. The Louisville, KY-based company plans to raise $150 million by offering 8.8 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Talaris Therapeutics would command a fully diluted market value...read more

Updated Monday, 5/3. 10 IPOs are expected to raise a total of $1.4 billion in the first week of May. The lineup is led by Jessica Alba’s highly-anticipated lifestyle brand, The Honest Company (HNST). The largest deal of the week, non-toxic lifestyle brand The Honest Company (HNST) plans to raise $400 million at a $1.6...read more